Analysts Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) PT at $21.00

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been assigned an average recommendation of “Buy” from the six ratings firms that are covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $21.00.

Separately, HC Wainwright began coverage on shares of Artiva Biotherapeutics in a report on Monday, December 30th. They issued a “buy” rating and a $20.00 target price for the company.

Artiva Biotherapeutics Trading Up 5.7 %

ARTV opened at $4.27 on Friday. The company has a 50 day simple moving average of $5.05 and a two-hundred day simple moving average of $9.51. Artiva Biotherapeutics has a 1-year low of $3.37 and a 1-year high of $17.31.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets purchased a new stake in Artiva Biotherapeutics in the 3rd quarter worth $42,000. China Universal Asset Management Co. Ltd. bought a new position in Artiva Biotherapeutics during the fourth quarter valued at approximately $52,000. Wells Fargo & Company MN boosted its stake in Artiva Biotherapeutics by 64.0% during the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock valued at $87,000 after buying an additional 3,361 shares during the last quarter. MetLife Investment Management LLC purchased a new position in Artiva Biotherapeutics during the 3rd quarter valued at approximately $135,000. Finally, JPMorgan Chase & Co. bought a new stake in Artiva Biotherapeutics in the 3rd quarter worth approximately $166,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.